Gain insights on preeclampsia risk stratification

Preeclampsia remains a serious hypertensive disorder of pregnancy, contributing to maternal and neonatal morbidity and mortality. This educational resource explores how PlGF and sFlt-1 biomarkers can support risk stratification for pregnant women at risk of progressing to preeclampsia with severe features.

Download the case study to learn more about the role of angiogenic factors in preeclampsia, key findings from the PRAECIS study, and how the sFlt-1/PlGF ratio can help inform short-term risk assessment in hospitalized pregnant women between 23 and 35 weeks of gestation

Learn how PlGF and sFlt-1 biomarkers may help stratify the risk of progression to preeclampsia with severe features.

What is preeclampsia? Preeclampsia is a severe complication related to hypertension affecting pregnant women. This life-threatening disease can

only be cured by the delivery of the baby and contributes largely to maternal and neonatal mortality and morbidity.

Preeclampsia can start from week 20 and happens up to 6

weeks after delivery

Fill out the form to download the full case study.

First name

Last name

Job Role

Specialty

Company/institution

Country / region

State

City

Zip / postal code

Phone number (optional)

I would like to receive emails about relevant Thermo Fisher Scientific information and promotions. By selecting this option, you are acknowledging that you have read and understand our Privacy Policy.

Thermo Fisher Scientific products are distributed globally and their uses, applications, indications, claims and availability of products in each country depend on local regulatory marketing authorization status, please consult the Instructions For Use (IFU) available in your country.

© 2026 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. B·R·A·H·M·S is a registered trademark of B·R·A·H·M·S GmbH.